Xalatan (latanoprost ophthalmic solution)


FDA approval of this prescription eye drop makes it the first and only prostaglandin with a first-line indication for the treatment of elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension. Initially, latanoprost was only approved for second-line use.

Related Content
© 2023 MJH Life Sciences

All rights reserved.